{
    "clinical_study": {
        "@rank": "163019", 
        "arm_group": [
            {
                "arm_group_label": "ASP7374 group", 
                "arm_group_type": "Experimental", 
                "description": "cell-culture-derived vaccine group"
            }, 
            {
                "arm_group_label": "TIV group", 
                "arm_group_type": "Active Comparator", 
                "description": "approved egg-derived TIV group"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to compare immunogenicity and safety of ASP7374 (cell-culture\n      derived influenza vaccine) with those of  approved egg-derived trivalent inactivated vaccine\n      (TIV) in elderly subjects."
        }, 
        "brief_title": "Phase-3 Study of ASP7374, Cell-culture-derived Influenza Vaccine", 
        "completion_date": {
            "#text": "March 2013", 
            "@type": "Actual"
        }, 
        "condition": "Influenza", 
        "condition_browse": {
            "mesh_term": "Influenza, Human"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Medically stable, as judged on the basis of history and concurrent diseases\n\n          -  Subject understands procedure of the protocol and is willing to comply with the\n             protocol\n\n        Exclusion Criteria:\n\n          -  Scheduled to receive another vaccine during the study\n\n          -  Received influenza HA vaccine within 180 days prior to screening\n\n          -  Received or scheduled to receive a live vaccine within 28 days prior to vaccination\n             with the study vaccine, and received or scheduled to receive an inactivated vaccine\n             or a toxoid within 7 days prior to vaccination with the study vaccine\n\n          -  Diagnosis of immune deficit in the past, has a family member (within the third degree\n             of kinship) with a diagnosis of congenital immunodeficiency syndrome\n\n          -  Received one of the following medications or treatment prior to vaccination with the\n             study vaccine: Interferon formulation, drugs which affect the immune system,\n             corticosteroids, G-CSF, M-CSF, human immunoglobulin products, blood products\n\n          -  History of anaphylactic shock or an allergic reaction such as generalized eruption\n             due to food or drug (including vaccines) allergies, fever \u226539.0\u00b0C within 2 days after\n             the previous vaccination (influenza vaccine and others)\n\n          -  History of seizures\n\n          -  History of Guillain-Barre syndrome or acute disseminated encephalomyelitis (ADEM)\n\n          -  Confirmed diagnosis of influenza within 84 days prior to screening test\n\n          -  Body temperature of \u226537.5\u00b0C on Day 1 (before vaccination)\n\n          -  Immunological tests reveal positive HBs antigen, HCV antibody, and HIV antigen and/or\n             antibody"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "65 Years"
        }, 
        "enrollment": {
            "#text": "1020", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "January 11, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01767896", 
            "org_study_id": "7374-CL-0103"
        }, 
        "intervention": [
            {
                "arm_group_label": "ASP7374 group", 
                "description": "subcutaneous (sc)", 
                "intervention_name": "ASP7374", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "TIV group", 
                "description": "subcutaneous (sc)", 
                "intervention_name": "approved egg-derived TIV", 
                "intervention_type": "Biological", 
                "other_name": "Influenza HA vaccine \"SEIKEN\""
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": "Influenza vaccine", 
        "lastchanged_date": "July 8, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Kansai", 
                        "country": "Japan"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kantou", 
                        "country": "Japan"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kyushu", 
                        "country": "Japan"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "2", 
        "official_title": "Phase III Study of ASP7374 \uff0dApproved Egg-derived Vaccine Controlled, Double-blind, Parallel Group Study in Elderly Subjects", 
        "overall_official": {
            "affiliation": "Astellas Pharma Inc", 
            "last_name": "Medical Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Japan: Pharmaceuticals and Medical Devices Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "March 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "evaluated for A/H1N1, A/H3N2, and B", 
                "measure": "seroconversion rate of hemoagglutination inhibition (HI) antibody titer", 
                "safety_issue": "No", 
                "time_frame": "Day 29"
            }, 
            {
                "description": "evaluated for A/H1N1, A/H3N2, and B", 
                "measure": "geometric mean titer (GMT) of HI antibody titer", 
                "safety_issue": "No", 
                "time_frame": "Day 29"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01767896"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "evaluated for A/H1N1, A/H3N2, and B", 
                "measure": "seroprotection rate of HI antibody titer", 
                "safety_issue": "No", 
                "time_frame": "Day 29"
            }, 
            {
                "description": "evaluated for A/H1N1, A/H3N2, and B", 
                "measure": "GMT ratio of HI antibody titer", 
                "safety_issue": "No", 
                "time_frame": "Day 1 and Day 29"
            }, 
            {
                "description": "evaluated for A/H1N1, A/H3N2, and B", 
                "measure": "seroconversion rate of neutralizing antibody titer", 
                "safety_issue": "No", 
                "time_frame": "Day 29"
            }, 
            {
                "description": "evaluated for A/H1N1, A/H3N2, and B", 
                "measure": "seroprotection rate of neutralizing antibody titer", 
                "safety_issue": "No", 
                "time_frame": "Day 29"
            }, 
            {
                "description": "evaluated for A/H1N1, A/H3N2, and B", 
                "measure": "GMT of neutralizing antibody", 
                "safety_issue": "No", 
                "time_frame": "Day 29"
            }, 
            {
                "description": "evaluated for A/H1N1, A/H3N2, and B", 
                "measure": "GMT ratio of neutralizing antibody", 
                "safety_issue": "No", 
                "time_frame": "Day 1 and Day 29"
            }
        ], 
        "source": "Astellas Pharma Inc", 
        "sponsors": {
            "collaborator": {
                "agency": "UMN Pharma Inc.", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Astellas Pharma Inc", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "July 2013"
    }
}